Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model

Chronic myelogenous leukemia (CML) is a hematological malignancy that begins as indolent chronic phase (CP) but inevitably progresses to fatal blast crisis (BC). p210BCR/ABL, a chimeric protein with enhanced kinase activity, initiates CML CP, and additional genetic alterations account for progression to BC, but the precise mechanisms underlying disease evolution are not fully understood. In the present study, we investigated the possible contribution of dysfunction of Bcl11b, a zinc‐finger protein required for thymocyte differentiation, and of H2AX, a histone protein involved in DNA repair, to the transition from CML CP to BC. For this purpose, we crossed CML CP‐exhibiting p210BCR/ABL transgenic (BAtg/–) mice with Bcl11b heterozygous (Bcl11b+/–) mice and H2AX heterozygous (H2AX+/–) mice. Interestingly, p210BCR/ABL transgenic, Bcl11b heterozygous (BAtg/–Bcl11b+/–) mice and p210BCR/ABL transgenic, H2AX heterozygous (BAtg/–H2AX+/–) mice frequently developed CML BC with T‐cell phenotype and died in a short period. In addition, whereas p210BCR/ABL was expressed in all of the leukemic tissues, the expression of Bcl11b and H2AX was undetectable in several tumors, which was attributed to the loss of the residual normal allele or the lack of mRNA expression. These results indicate that Bcl11b and H2AX function as tumor suppressor and that haploinsufficiency and acquired loss of these gene products cooperate with p210BCR/ABL to develop CML BC. (Cancer Sci 2009; 100: 1219–1226)

[1]  B. Wainwright,et al.  Canonical Notch signaling is not required for the growth of Hedgehog pathway-induced medulloblastoma , 2010, Oncogene.

[2]  Yves Pommier,et al.  γH2AX and cancer , 2008, Nature Reviews Cancer.

[3]  George Iliakis,et al.  γ-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin , 2008, Nucleic acids research.

[4]  N. Gooderham,et al.  Early events in the mammalian response to DNA double-strand breaks. , 2008, Mutagenesis.

[5]  M. Ochi,et al.  Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice , 2008, Oncogene.

[6]  N. Copeland,et al.  BCL11B is required for positive selection and survival of double-positive thymocytes , 2007, The Journal of experimental medicine.

[7]  Joseph M. Connors,et al.  Genetic Variation in H2AFX Contributes to Risk of Non–Hodgkin Lymphoma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[8]  Junia V. Melo,et al.  Chronic myeloid leukaemia as a model of disease evolution in human cancer , 2007, Nature Reviews Cancer.

[9]  R. Kominami,et al.  Haploinsufficiency of Bcl11b for suppression of lymphomagenesis and thymocyte development. , 2007, Biochemical and biophysical research communications.

[10]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[11]  R. Siebert,et al.  Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL , 2005, Leukemia.

[12]  P. Pandolfi,et al.  Role of Dok-1 and Dok-2 in Leukemia Suppression , 2004, The Journal of experimental medicine.

[13]  B. Calabretta,et al.  The biology of CML blast crisis. , 2004, Blood.

[14]  T. Ried,et al.  H2AX Haploinsufficiency Modifies Genomic Stability and Tumor Susceptibility , 2003, Cell.

[15]  F. Alt,et al.  Histone H2AX A Dosage-Dependent Suppressor of Oncogenic Translocations and Tumors , 2003, Cell.

[16]  S. Aizawa,et al.  Bcl11b is required for differentiation and survival of αβ T lymphocytes , 2003, Nature Immunology.

[17]  A. Matsuki,et al.  Homozygous deletions and point mutations of the Rit1/Bcl11b gene in gamma-ray induced mouse thymic lymphomas. , 2003, Biochemical and biophysical research communications.

[18]  T. Inaba,et al.  Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. , 2003, Blood.

[19]  T. Kawamoto,et al.  Identification of Functional Hypoxia Response Elements in the Promoter Region of the DEC1 and DEC2 Genes* , 2002, The Journal of Biological Chemistry.

[20]  F. Alt,et al.  Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D G Oscier,et al.  The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. , 2001, Blood.

[22]  Y. Yazaki,et al.  Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. , 2000, Blood.

[23]  Y. Yazaki,et al.  Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. , 1998, Blood.

[24]  Y. Yazaki,et al.  Establishment, characterization, and chromosomal analysis of new leukemic cell lines derived from MT/p210bcr/abl transgenic mice. , 1998, Experimental Hematology.

[25]  O. Witte,et al.  Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. , 1993, Proceedings of the National Academy of Sciences of the United States of America.